共 74 条
[1]
Miligkos M(2016)efficacy and safety profile of anti-tumor necrosis factor-α versus anti-integrin agents for the treatment of Crohn’s disease: a network meta-analysis of indirect comparisons Clin Ther 38 1342-1358
[2]
Papamichael K(2015)Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target Am J Gastroenterol 110 1324-1338
[3]
Vande Casteele N(2017)Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy Am J Gastroenterol 112 673-676
[4]
Peyrin-Biroulet L(2017)Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy Am J Gastroenterol 112 673-676
[5]
Sandborn W(2017)Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab Clin Gastroenterol Hepatol 15 1580-1588
[6]
Sands BE(2016)Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases Clin Gastroenterol Hepatol 14 550-557
[7]
Papamichael K(2016)Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn’s disease and ulcerative colitis Inflamm Bowel Dis 22 409-415
[8]
Cheifetz AS(2017)Infliximab and adalimumab drug levels in Crohn’s disease: contrasting associations with disease activity and influencing factors Aliment Pharmacol Ther 46 150-161
[9]
Papamichael K(2017)Post-induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis J Crohns Colitis 11 53-59
[10]
Cheifetz AS(2016)Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn’s disease J Crohns Colitis 10 507-509